key: cord-0862656-xyqlcboa
authors: El-hoshoudy, A.N.
title: Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation
date: 2020-08-04
journal: J Mol Liq
DOI: 10.1016/j.molliq.2020.113968
sha: 12ed964ee4d0a569ea933b65ceb3b8b64632e77d
doc_id: 862656
cord_uid: xyqlcboa

Recently, scary viral pneumonia is known as (COVID-19) has swept the whole world. The new virus strain designated as SARS-CoV-2 belonging to the coronavirus family. Although the current medical research directed towards the development of a novel therapeutic agent, no anti-viral drug approved until now. On the medical scale, the development of an approved drug is a time-consuming process, so research is directed towards screening of ligands and drugs multimodal structure-based-design and then docked to the main viral protease to investigate the active binding sites. The bioinformatic approaches used to evaluate the competence of a comprehensive range of ligands and drugs before their clinical implementation. In this study, a computational approach through molecular docking simulation is conducted for screening the antiviral activity of drugs, natural sources, and inhibitory compounds against the SARS-CoV-2 genome. The main virus protease was collected from a Protein Data Bank (PDB# 6YB7) and docked with a sequence of 19 approved antiviral drugs, 10 natural inhibitory ligands against COVID-19 downloaded from PubChem, in addition to 10 natural sources optimized for Escherichia coli BL(21) (DE(3)) to identify the antiviral activity of these candidates against COVID-19. The docking results were promised and indicated that the reported ligands can firmly bind to the SARS-CoV-2 main protease and leads to inhibition of its infectious impact.

J o u r n a l P r e -p r o o f boundary to reveal S2 for combination to the cell membrane [2, 32, 33] . For all coronaviruses, the S protein is further cleaved by host proteases [34] . S trimers are densely decorated by heterogeneous Nlinked glycans protruding from the trimer surface and important for proper folding and modulating availability to host proteases and neutralizing antibodies [2, 35, 36] . SARS-CoV-2 is an enveloped, positive single RNA strand coronavirus with a genome sequence ranging from 26.0 to 32.0 kilobases [37] [38] [39] . On 10 th January 2020, the viral genome was released on NCBI GenBank. The first high-resolution crystal structure of SARS-CoV-2 main protease released on February 5 th , 2020 on Protein Data Bank (PDB) Doi: 10 .2210/pdb6lu7/pdb [1, 2, 7] . 6LU7 is the monomer of the main protease in the active state with the N3 peptidomimetic inhibitor [40] . On 25 th March 2020, 6YB7 released as SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, DOI: 10 .2210/pdb6YB7/pdb. Although the current medical research proceeds urgently to diagnose active antiviral agents that can inhibit the pandemic spread of the novel viral infection, no targeted/approved therapeutic drug or vaccine has been accredited till now as it is a time-consuming process [1, 10, 31, 41] .

Consequently, the swift approach relies on the use of computational programs of combined structureassisted drug design, bioinformatics, and drug screening [10, 42] , in addition to the development of a predictive 3D protein structures of SARS-CoV-2 has become very crucial to identify new inhibitory drugs for SARS-CoV-2 protease [7, 43] . Roboson [7] stated the usage of the Q-UEL computational method to simulate the inhibition efficiency of some drugs on COVID-19. In this work, the author conducting a computational approach, through applying a combination of virtual screening, and molecular docking techniques, to assess the ability of some potential drugs, inhibitory ligands and natural products for the non-covalent inhibition of the SARS-CoV-2 main protease [40] through conformational and molecular docking studies. Molecular docking allows quick identification of the amino acid sequences across many coronaviruses including SARS-CoV-2 [7, 44] . The obtained docking results were hopeful and proposed a potential inhibition against the newly emerged COVID-19 from the presently accessible therapeutics [1] .

All the screened drugs, inhibitory ligands, and natural product structures were built up from their smile format in ChemBioDraw 2019 software. All the molecules were energy minimized before molecular docking simulation [31] . The screened compounds comprise three categories divided as follows; 19

approved antiviral drugs presently available on the market and have been authorized for use against a variety of viruses. 10 natural inhibitors ligands against COVID-19 were downloaded from PubChem 0Information%20Processing. The full-length gene encoding COVID-19 virus was optimized for Escherichia coli BL21 (DE3) expression [10] . Tables 1-3 summarize the structure of the compounds for the three categories respectively. 14 Ribavirin HCV antiviral [37] J o u r n a l P r e -p r o o f 

The recently emerged SARS-CoV-2 nucleotide gene was retrieved from the protein data bank (PDB ID:

6YB7, chain A) since it is the last approved SARS-CoV-2 main protease during the editing of this manuscript. 6YB7 is the monomer of the main protease with the unliganded active site [40] . The sequence was downloaded as a PDB format. 6YB7 is SARS-CoV-2 main protease with 306 sequence length and 1.25 Å resolution. The protein sequence stated in Table 4 , while the crystal 3D structure of COVID-19 main protease shown in Figure 1 . The model validated by Molecular operating Environment (MOE 2015.1) software after the addition of missed hydrogen atoms to prepare the protonated 3D-structure for the docking study [14] . After validation, the systems were energy-minimized [50] to obtain a fully optimized and stable structure for further docking simulation. Energy minimization carried out using Amber10: EHT forcefield with current forcefield charges applied to all atoms, R-field solvation, cutoff 

In this study, the SARS-CoV-2 main protease was retrieved from the protein data bank (PDB ID: 6YB7, chain A) [14] . After model validation, alignment of the protein sequences, and subsequent molecular docking conducted by Molecular operating Environment (MOE2015.1) software to evaluate the antiviral effect of the previously reported drugs, and natural sources against SARS-CoV-2 protease. The binding energies and the inhibition constants are reported in each case [44] . All of the compounds were optimized in their active physiological settings [51] . Before testing the ligands against SARS-CoV-2 protease, the structures of the tested drugs and ligands were ensured to be in the optimized active arrangement. Finally, the ligands selected based on analyzing the predicted binding modes and their scores [10] .

Compounds with lower molecular docking scores will have higher binding correspondences with the target 6YB7 protein [1] . The orientation of a ligand is evaluated with a shape-scoring function which approximates the binding energies of the ligand-receptor. The shape-scoring function is an empirical function resembling the van der Waals' attractive energy. After the initial orientation and scoring evaluation, energy minimization is conducted to pinpoint the closest energy minimization points within the receptor-binding sites [47] . The ligand-protein docking was conducted according to the manual of [40] and exhibit excessive H-bonding, π-π interaction and/or hydrophobic interaction with the 6YB7 protease as summarized in Tables 5-7 . These electrostatic interactions imply that these ligands are potent inhibitors for the SARS-CoV-2 protease [1] , since, the formed complex between the screened ligands and SARS-CoV-2 main protease is highly stable with higher binding energies. The formation of excessive hydrogen bonding with the main protease chain indicates the ability of the ligand to lock the virus-binding receptor [10] . By analyzing the docking results, it's found that Ritonavir antiviral drug, (Tables S1-S3 ). Based on the binding energies and docking scores, Ritonavir antiviral drug considered as the strongest inhibiting agent rather than other screened 39 ligands with a higher binding energy of -8.12 kcal/mol. Furthermore, Ritonavir found to have a strong binding pattern with aromatic moieties, so it is the most potent docked ligands [40] . The docking study exhibited that the screened ligands inhibit coronaviruses and illuminate the road for medical scientists to develop in-vivo and in-vitro compounds against COVID-19. 

The newly emerged COVID-19 virus is a serious health concern in the 20 th century. Although there is a sequence of medical drugs and natural products demonstrated high binding affinity to various viral proteins, the development of an in-vivo and in-vitro medical inhibitory drug for SARS-CoV-2 is a challenging and time-consuming task. As a result, in silico and bioinformatic routes is a fast way to assess an effective drug against SARS-CoV-2. A rigorous computational docking was pursued to identify the antiviral activity of any drug before medical usage. The present study screened the inhibitory effect of 39 ligands based on molecular docking of 6YB7 protease. The docking results exhibited that the reported ligands exhibit a high binding affinity to the COVID-19 protease and can inhibit its viral infection.

Ritonavir antiviral drug binds to SARS-CoV-2 main protease with a score of -8.12, so it is expected that ritonavir is a potent inhibitor for SARS-CoV-2 pneumonia. The results obtained in this study are based on computer docking simulation, and no in vivo and in vitro anti-viral assessment conducted till now, since the author aims to share these results with medical scientists to face SARS-CoV-2 epidemic urgently.

The authors declare that they have no known competing for financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Possible Importance of the KRSFIEDLLFNKV Motif, Circulated and Published on ResearchGate

Annual review of virology

J o u r n a l P r e -p r o o f

Conducted all the work done in this research article.

The author declares that there is no conflict of interest.